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Introduction
The prevalence of oesophageal carcinoma has increased
dramatically in the last 30 years with reported increases
of 350–800%. [1] Adenocarcinoma is now the most
common cell type in the United States, and although
the disease may present late it should not be considered
an entity with a uniformly poor prognosis. The overall
5-year survival is 25%, increasing to 85% if the
nodes are disease-free at presentation. Unfortunately,
approximately 75% of patients will have evidence
of nodal disease at presentation and 18% will have
distant metastases. [2] Appropriate staging is important
for assessment of prognosis and deciding the most
appropriate therapy. Treatment options include curative
and palliative surgery, chemo-radiotherapy and stent
insertion.
Staging
Staging is based on depth of tumour invasion (T stage),
regional node involvement (N stage) and the presence of
metastases (M stage). The TNM classification and the
stage groupings are shown in Table 1.
Non-invasive methods of staging include computerised
tomography (CT), endoscopic ultrasound (EUS) and
positron emission tomography (PET). Magnetic reso-
nance imaging (MRI) has no real advantage over CT,
is not commonly used and will not be included in this
review.
Table 1 Staging of oesophageal cancer — TNM
system
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour invades lamina propria or submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades adventitia
T4 Tumour invades adjacent structures
N0 No regional nodes
N1 Regional nodal metastases — cervical, mediastinal
and perigastric
M0 No distant spread
M1 Distant spread
Lower oesophagus
M1a — metastases in coeliac nodes, M1b — distant metastases
Upper oesophagus
M1a — metastases in cervical nodes, M1b — distant metastases
Mid-oesophagus
M1a — not apply, M1b — non regional nodes, distant metastases
Stage
0 Tis N0 M0
1 T1 N0 M0
11A T2 N0 M0
T3 N0 M0
11B T1 N1 M0
T2 N1 M0
111 T3 N1 M0
T4 N0/1 M0
IV T1-4 N0/1 M1
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Figure 1 Endoscopic ultrasound of patients with
oesophageal cancer with mediastinal invasion. (a) Oe-
sophageal tumour (T4): the tumour (white arrow) is
adherent to the left pulmonary vein (white cross) with
loss of the intervening plane. (b) Oesophageal tumour
(T4): the tumour (broken white arrow) has breached
the pleura (white arrow) to invade the right lung.
T Stage
This is defined as the depth of tumour invasion through
the oesophageal wall and adequate T staging requires
identification of the individual layers of the wall. T1 to
T3 tumours are confined to the oesophagus and may be
suitable for surgical resection, while T4 tumours extend
beyond the oesophageal wall into adjacent structures and
are not suitable for surgical intervention.
Endoscopic ultrasound (EUS)
The oesophageal wall can be resolved into individual
layers and is seen as five layers of alternating echogenic-
ity. This definition allows accurate determination of the
depth of tumour invasion depending on which layer is
infiltrated. [3]
The tumour usually appears as circumferential thick-
ening of the wall of hypoechoic or mixed echo pattern
with distortion of the layers. Accurate assessment of the
depth of invasion through the mucosa, submucosa and
muscularis propria can be made. T1 and T2 tumours
can be differentiated and extension of tumour through
the oesophageal wall and invasion into the surrounding
structures identified (Fig. 1).
The accuracy of staging using EUS is dependent not
only on operator experience but also on the actual T stage,
being better for T4 than for T1 tumours. In a meta-
analysis of several series, [4] the overall accuracy was
84%. For T1 tumours it was 83.5% with 16.5% over-
staged; for T2 tumours 73% with 10% under-staged and
17% over-staged; for T3 tumours 89% with 5% under-
staged and 6% over-staged and for T4 tumours 89% with
11% under-staged. The variation in the quoted accuracy
in published studies is quite high, ranging from 75–82%
for T1, 64–85% for T2, 89–94% for T3 and 88–100% for
T4. [5] In a more recent study of EUS in T1 to T3 tumours
an accuracy of only 64% was achieved with 19% over-
staged and 17% under-staged. [6]
A limitation of EUS is that oesophageal stenosis can
prevent complete staging in 19 to 63% of tumours, [7]
although this problem may be overcome by use of
miniature ultrasound probes or by attempted dilatation of
the stricture.
EUS is the best method for assessment of T stage.
Computerised tomography (CT)
The normal oesophageal wall is less than 3 mm on CT,
and individual layers cannot be identified, so T1 and T2
tumours cannot be differentiated. Invasion of the peri-
oesophageal fat may be seen as ill-defined soft tissue
stranding but T3 tumours cannot be accurately assessed.
T4 tumours are inferred by the loss of fat planes between
the tumour and adjacent structures, although this may be
difficult in very thin patients (Fig. 2). Aortic invasion,
which is found in only 6% of patients at post mortem,
is diagnosed if the angle of contact between the tumour
and aorta is greater than 90◦, if the angle of contact is
less than 45◦ there is no invasion. Using this criterion
produces a large number of indeterminate results and an
overall accuracy of 55%, [8] and loss of the triangular fat
space between the oesophagus, aorta and spine is a better
sign of invasion with an improved accuracy of 86%. [9]
Bowing of the posterior wall of the trachea or left
main stem bronchus suggests airway invasion (sensitivity
= 71%, specificity = 91%, and accuracy = 88%); this
requires bronchoscopy for confirmation.
The main value of CT in T staging is to exclude T4
tumours, which will preclude surgery.




Figure 2 (a) CT scan of patient with oesophageal
cancer showing infiltration into the mediastinum with
aortic invasion (T4 tumour). (b) PET scan of the
same patient showing oesophageal uptake but the
extent of mediastinal invasion is not clearly identified.
(c) PET scan of the same patient with uptake in lung
metastasis (arrow) not seen on the CT.
Positron emission tomography (PET)
The most commonly used isotope for oncology imaging
is 2-18fluoro-2-deoxy-D-glucose (FDG). This glucose
analogue can differentiate malignant from normal cells
based on the increased accumulation in malignant cells
partly as a result of the enhanced glycolysis; thus
both the the primary tumour and distant metastases can
be identified. [10] Both adenocarcinoma and squamous
carcinoma of the oesophagus demonstrate increased FDG
uptake. The reported sensitivity for detecting the primary
tumour is 91–100%, but increased uptake may also be
seen in oesophagitis. False-negative results may occur in
very small T1 tumours. [6]
PET has the advantage of being a whole body imaging
method, however, the spatial resolution is relatively poor
(5 mm) when compared with CT, and image registration
may be required to improve anatomic localization. The
poor spatial resolution means mediastinal invasion cannot
be assessed accurately and PET should not be used for
T staging (see Fig. 2).
N Stage
Lymphatic involvement is common, particularly with
squamous cell carcinoma, where there is early spread
through interconnecting lymphatics, so that the site of the
primary lesion does not indicate which lymph nodes will
be involved. Thirty-two per cent of upper third tumours
will have involved abdominal nodes and in lower third
tumours abdominal nodal disease is more common than
mediastinal.
Nodal staging is based on infiltration of local nodes
only, however, the number of nodes involved is an
important prognostic indicator (more than four nodes
or greater than 10% of nodes involved carries a poor
prognosis). The presence of metastases in the peri-
oesophageal nodes does not preclude surgery, as they will
be removed en bloc at the time of resection. The normal
size used for supraclavicular nodes is less than 5 mm,
mediastinal nodes less than 1 cm in short axis, 6 mm
for retro-crural nodes and 6–8 mm for left gastric nodes.
Using size as a criterion has limitations as normal-sized
nodes may contain micro-metastases and enlarged nodes
may be reactive rather than neoplastic.
Endoscopic ultrasound (EUS)
EUS can define the size, borders and internal structure
of nodes. Nodes greater than 1 cm, that are round,
hypoechoic, non-homogeneous and well defined are
more likely to be malignant. Small, oval, hyperechoic,
homogeneous nodes with indistinct borders are more
likely to be benign. In one study the sensitivity of EUS
was 89%, specificity 75% and accuracy 84% with a
positive predictive value (PPV) for N1 disease of 86%
and a negative predictive value (NPV) of 79%. If all the
malignant features were identified the accuracy increased
to 100%. [11] A limitation of EUS is that only 30% of
nodes identified at surgery will be visualized, with size an
important limiting factor. EUS will identify 92% of nodes
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Figure 3 CT of patient with oesophageal cancer and
liver metastases and peri-oesophageal lymph node
(arrowhead).
greater than 10 mm, 53% of nodes between 5 and
9 mm and only 1% of nodes less than 5 mm. [12]
The accuracy for assessment of lymph nodes in non-
traversable strictures may be as low as 10%.
Endoluminal ultrasound overestimates lymph node
disease because of difficulties in differentiating between
infiltration and inflammation and thus has a limited
specificity. Generally, EUS is better at diagnosing
malignant nodes rather than benign nodes (accuracy 89%
for N1 and 69% for N0 disease).
Accuracy is highest for peri-oesophageal nodes and
varies inversely with the axial distance of the nodes from
the oesophageal axis. [13] It is also important to remember
that the incidence of nodal disease depends on the T stage
of the tumour ranging from 17% for T1 tumours to 88%
for T4 tumours.
EUS can also be used in association with fine needle
aspiration to produce excellent results with a reported
sensitivity of 92%, specificity of 93%, PPV of 100% and
negative predictive value (NPV) of 86%. [14]
Computerised tomography (CT)
CT has well-known limitations in the accuracy of nodal
staging as size is used as the only criterion. Small
lymph nodes containing metastases, particularly the peri-
oesophageal nodes, will not be diagnosed as infiltrated
and the patient will be under-staged (Fig. 3). False-
positive examinations are due to enlarged inflammatory
nodes being called malignant, and, as it is important not
to over-stage patients and deprive them of potentially
curative surgery, any enlarged node on CT should have
tissue confirmation if this CT finding alone would
change therapy. If mediastinal lymph nodes with a short
axis greater than 10 mm are considered abnormal, the
accuracy for CT diagnosis of node involvement is 51–
70%. In one series the sensitivity was 19% with a PPV of
33% and in this series only 28% of the metastatic nodes
were greater than 10 mm in size, 35% were 5–9 mm
and 36% were less than 5 mm. [15] Consigliere [16] found
that CT had an overall accuracy of 69% for detection of
nodal enlargement, however, only 38% of the identified
enlarged nodes were malignant and 57% of unidentified
normal-sized nodes contained tumour.
A recent study [17] using thin section (5 mm) spiral
CT in gastro-oesophageal adenocarcinoma found that CT
detected only 21% of all the nodes identified at surgery
irrespective of histology. Detection was dependent on the
size of the nodes with only 1% of nodes measuring less
than 4 mm identified, 45% of nodes measuring less than
5–9 mm, and 72% of nodes greater than 9 mm in size.
2-18fluoro-2-deoxy-D-glucose positron
emission tomography (FDG PET)
Uptake of FDG is dependent on metabolic activity not
size of nodes and therefore FDG PET will identify
tumour in normal size lymph nodes (Fig. 4). A limitation
in local nodal staging is the poor spatial resolution. False-
negative studies occur with nodes situated very close
to the primary that may not be identified as separate
from it and in very small nodes or nodes containing
micrometastases. False-positive results are a result of
uptake of FDG PET in non-malignant inflammatory
nodes such as those involved with tuberculosis or
sarcoidosis. Positive nodes on PET should therefore be
sampled if management will be altered. Nevertheless, the
results appear to be promising with a reported sensitivity
of 33%, specificity 89% and accuracy 59%. [6] In this
study the low sensitivity for local nodes on FDG PET
contrasted with the results of EUS which had a sensitivity
of 81%, with specificity of 67% and accuracy of 74%.
M Stage
Distant metastases are common and approximately 18%
of patients will have metastases at presentation. The most
common sites are abdominal lymph nodes (45%), liver
(35%), lung (20%) supraclavicular nodes (18%), bone
(9%), and adrenals (5%); other sites including the brain,
peritoneum and pericardium are rarely involved.
The M stage has been modified for tumours of the
upper and lower oesophagus to differentiate non-regional
nodal metastases from other metastatic sites (Table 1).
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Figure 4 (a) CT scan of patient with oesophageal
cancer. No evidence of mediastinal invasion. (b) Coro-
nal PET scan of same patient showing uptake
in tumour (arrow) and also in mediastinal node
(arrowhead) not seen on CT.
Endoscopic ultrasound (EUS)
EUS has a role in assessing the non-regional lymph
node groups, particularly the peri-gastric and coeliac
nodes (sensitivity = 83%, specificity = 98%, accuracy =
95%, PPV = 91%, NPV = 97%), therefore staging M1a
disease, but has a limited role for M1b disease. EUS will
not depict organ metastases unless the organ is in direct
contact with the upper GI tract (e.g. left lobe of the liver).
Computerised tomography (CT)
Liver metastases greater than 2 cm are well demonstrated
on CT using contrast-enhanced portal phase imaging with
overlapping reconstruction, with reported sensitivities of
70–80% (see Fig. 3). Sub-centimetre metastases may be
missed and are better identified on laparoscopy. However,
characterization of small lesions, less than 1.5 cm, is
difficult and as up to 50% of small lesions, particularly
if solitary, may be benign biopsy proof is important,
especially if management would be altered. [18,19]
CT is poor at diagnosing peritoneal deposits that occur
with adenocarcinoma but not squamous cell carcinoma,
with a reported sensitivity of 21% compared with 96%
for laparoscopy. CT is also sensitive for the detection of
lung metastases although benign granulomatous lesions
are difficult to differentiate from metastases. [20]
The diagnosis of abdominal lymph node involvement
has the same problems as elsewhere in the body with a
reported sensitivity for left gastric node involvement of
48%, specificity of 93% and accuracy of 79%. [21]
Overall, the sensitivity of CT for screening for distant
metastases is 41–62%, with specificity of 69–83% and
accuracy of 63–90%. [6,22,23]
Positron emission tomography (PET)
PET is an excellent method for screening for distant
metastases and is superior to CT (see Fig. 2). In a
study of 91 patients, 70 metastatic sites were confirmed
on biopsy. The sensitivity for FDG PET was 69% (CT
46%), specificity 93% (CT 74%) and accuracy 84% (CT
63%). [22] In this study 10 liver, 4 pleural, 2 lung and
1 peritoneal deposits were missed, all lesions being less
than 1 cm in size. In the 21 false-negative CT scans
the PET was positive in 11 (62%) and in the 12 false-
negative PET scans the CT was positive in 4 (33%). Other
studies [6] comparing FDG-PET to the combination of
EUS and CT found similar results with a sensitivity of
74% (CT/EUS 47%), specificity 90% (CT/EUS 78%) and
accuracy 82% (CT/EUS 64%). In this study PET under-
staged the extent of nodal disease in 19 (49%), whereas
the CT/EUS combination over-staged the nodal stage in
14 (36%). The high false-negative rate for PET may be a
result of the high incidence of micrometastases.
Conclusions (Tables 2 and 3)
EUS is the best method for the T stage; it is also the
most sensitive method for the assessment of local nodes
but has limited specificity. CT is readily available and is
best for advanced disease. FDG PET is best for distant
metastases and regional nodal metastases, although is not
widely available.
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Table 2 Accuracy of techniques for TNM stag-
ing [4,6,11,16,22]
T stage N stage (%) M stage
EUS 84% 84 N/A
CT N/A 69 63%
FDG-PET N/A 59 84%
Table 3 Comparison of techniques
Good for Poor for



















T stage and local
invasion
Local nodes
Most patients present with advanced disease, therefore
the standard staging algorithm will often be an initial
CT. In those patients considered suitable for resection
EUS is then performed for accurate local staging and
FDG PET should be used if the previous studies suggest
locally resectable disease, to exclude distant metastases
undetected by CT.
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